TABLE I.
Demographic and disease characteristics at baseline in the intention-to-treat population
| Characteristic | Patient group | |
|---|---|---|
| zol | Control | |
| Patients (n) | 151 | 157 |
| Age (years) | ||
| Median | 56.4 | 57.8 |
| Range | 29–65 | 33–65 |
| Sex [n (%)] | ||
| Male | 71 (47) | 85 (54) |
| Female | 80 (53) | 72 (46) |
| Risk [n (%)]a | ||
| High | 134 (89) | 138 (88) |
| Intermediate | 17 (11) | 19 (12) |
| Stage (Durie–Salmon) | ||
| iib | 11 (8) | 19 (12) |
| iiia | 2 (1) | 2 (1) |
| iiib | 138 (90) | 136 (86) |
| Myeloma type [n (%)] | ||
| Immunoglobulin G | 110 (73) | 108 (69) |
| Immunoglobulin A | 21 (14) | 30 (19) |
| Light chain | 10 (7) | 9 (6) |
| Nonsecretory | 10 (7) | 10 (6) |
| Anemia [n (%)] | 151 (100) | 157 (100) |
| Hypercalcemia [n (%)] | 38 (25) | 27 (17) |
| Renal failure [n (%)] | 17 (11) | 21 (13) |
| Bone lesions [n (%)] | 151 (100) | 157 (100) |
| β2-Microglobulinb [n (%)] | 151 (100) | 157 (100) |
| ecog performance status [n (%)] | ||
| 0–1 | 0 | 0 |
| 2 | 96 (64) | 99 (63) |
| >2 | 55 (36) | 58 (37) |
a
Based on the International Staging System19.
b
Exceeding twice the upper limit of normal.
zol = zoledronic acid; ecog = Eastern Cooperative Oncology Group.